{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:43:29Z","timestamp":1786175009137,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005934","name":"Malm\u00f6 University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005934","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>ISA-2011B is a phosphatidylinositol-4-phosphate 5-kinase-\u03b1 (PIP5K1\u03b1) inhibitor that has been reported to be selective in suppressing the growth of prostate, breast and hepatic cancer cells. Here, cell viability of 2-dimensional (2D) cultures and 3-dimensional (3D) spheroids of four colorectal cancer (CRC) cell lines with different mutations were evaluated after treatment with the drug ISA-2011B. Methods: The CRC cell lines were investigated for viability in 2D and 3D spheroid cultures. The 3D spheroids were subjected to imaging, and the average volumes were measured. Results: The results show different treatment effects of ISA-2011B on the four CRC cell lines, indicating that mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol 3-kinase (PI3K) genes can play a role in the outcome of treatment. Conclusions: With additional studies, we suggest that ISA-2011B can be a promising drug target in CRC.<\/jats:p>","DOI":"10.1007\/s11033-026-12495-2","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:02:57Z","timestamp":1786172577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Veroniaina","family":"Hanitrarimalala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette Gj\u00f6rloff","family":"Wingren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"12495_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2148-11-4","volume":"11","author":"JR Brown","year":"2011","unstructured":"Brown JR, Auger KR (2011) Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol Biol 11:4","journal-title":"BMC Evol Biol"},{"issue":"10","key":"12495_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12032-022-01753-5","volume":"39","author":"M Yin","year":"2022","unstructured":"Yin M, Wang Y (2022) The role of PIP5K1A in cancer development and progression. Med Oncol 39(10):151","journal-title":"Med Oncol"},{"key":"12495_CR3","doi-asserted-by":"crossref","unstructured":"Semenas J, Hedblom A, Miftakhova RR, Sarwar M, Larsson R, Shcherbina L et al (2014) The role of PI3K\/AKT-related PIP5K1\u03b1 and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proceedings of the National Academy of Sciences. ;111(35):E3689-E98","DOI":"10.1073\/pnas.1405801111"},{"issue":"3","key":"12495_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41388-018-0438-2","volume":"38","author":"M Sarwar","year":"2019","unstructured":"Sarwar M, Syed Khaja AS, Aleskandarany M, Karlsson R, Althobiti M, \u00d8dum N et al (2019) The role of PIP5K1\u03b1\/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1\u03b1 inhibitor. Oncogene 38(3):375\u2013389","journal-title":"Oncogene"},{"key":"12495_CR5","doi-asserted-by":"crossref","unstructured":"Shantanu PA, Rajdev B, Syamprasad NP, Gangasani JK, Mandal A, Panda SR et al (2026) Targeting PIP5K ameliorates hepatic cancer by inhibiting PI3K\/AKT and the autophagy mechanism and enhancing ROS-mediated apoptosis. Front Pharmacol. ;Volume 17\u20132026","DOI":"10.3389\/fphar.2026.1791462"},{"issue":"30","key":"12495_CR6","doi-asserted-by":"publisher","first-page":"e04372","DOI":"10.1002\/advs.202504372","volume":"12","author":"M Guo","year":"2025","unstructured":"Guo M, Chen S, Sun J, Xu R, Qi Z, Li J et al (2025) PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Adv Sci 12(30):e04372","journal-title":"Adv Sci"},{"issue":"3","key":"12495_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mpo.2950120314","volume":"12","author":"CP Spears","year":"1984","unstructured":"Spears CP (1984) Volume doubling measurement of spherical and ellipsoidal tumors. Med Pediatr Oncol 12(3):212\u2013217","journal-title":"Med Pediatr Oncol"},{"issue":"6","key":"12495_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-14-0792","volume":"14","author":"W Senkowski","year":"2015","unstructured":"Senkowski W, Zhang X, Olofsson MH, Isacson R, H\u00f6glund U, Gustafsson M et al (2015) Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer. Mol Cancer Ther 14(6):1504\u20131516","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"12495_CR9","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/oncsis.2013.35","volume":"2","author":"D Ahmed","year":"2013","unstructured":"Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Ekn\u00e6s M, Hektoen M et al (2013) Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2(9):e71\u2013e","journal-title":"Oncogenesis"},{"issue":"11","key":"12495_CR10","doi-asserted-by":"publisher","first-page":"e0188100","DOI":"10.1371\/journal.pone.0188100","volume":"12","author":"A Virgone-Carlotta","year":"2017","unstructured":"Virgone-Carlotta A, Lemasson M, Mertani HC, Diaz J-J, Monnier S, Dehoux T et al (2017) In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil. PLoS ONE 12(11):e0188100","journal-title":"PLoS ONE"},{"issue":"3\u20134","key":"12495_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000015545","volume":"88","author":"Y Xie","year":"2000","unstructured":"Xie Y, Zhu L, Zhao G (2000) Assignment of type I phosphatidylinositol-4-phosphate 5-kinase (PIP5K1A) to human chromosome bands 1q22\u2013> q24 by in situ hybridization. Cytogenet Cell Genet 88(3\u20134):197\u2013199","journal-title":"Cytogenet Cell Genet"},{"issue":"7092","key":"12495_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Cantley LC, Ras (2006) PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424\u2013430","journal-title":"Nature"},{"issue":"12","key":"12495_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K\/AKT Pathway for Cancer Drug Discovery. Nat Rev Drug Discovery 4(12):988\u20131004","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"12495_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4161\/cc.5.5.2538","volume":"5","author":"PR Somanath","year":"2006","unstructured":"Somanath PR, Razorenova OV, Chen J, Byzova TV (2006) Akt1 in endothelial cell and angiogenesis. Cell Cycle 5(5):512\u2013518","journal-title":"Cell Cycle"},{"issue":"1","key":"12495_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41467-020-20887-6","volume":"12","author":"PAJ Mendelaar","year":"2021","unstructured":"Mendelaar PAJ, Smid M, van Riet J, Angus L, Labots M, Steeghs N et al (2021) Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nat Commun 12(1):574","journal-title":"Nat Commun"},{"key":"12495_CR16","doi-asserted-by":"publisher","first-page":"798590","DOI":"10.3389\/fcell.2022.798590","volume":"10","author":"T Wang","year":"2022","unstructured":"Wang T, Sarwar M, Whitchurch JB, Collins HM, Green T, Semenas J et al (2022) PIP5K1\u03b1 is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer. Front Cell Dev Biol 10:798590","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"12495_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/1878-0261.12873","volume":"15","author":"J Semenas","year":"2021","unstructured":"Semenas J, Wang T, Sajid Syed Khaja A, Firoj Mahmud A, Simoulis A, Grundstr\u00f6m T et al (2021) Targeted inhibition of ER\u03b1 signaling and PIP5K1\u03b1\/Akt pathways in castration-resistant prostate cancer. Mol Oncol 15(4):968\u2013986","journal-title":"Mol Oncol"},{"issue":"3","key":"12495_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcmgh.2020.04.007","volume":"10","author":"A Prossomariti","year":"2020","unstructured":"Prossomariti A, Piazzi G, Alquati C, Ricciardiello L (2020) Are Wnt\/\u03b2-Catenin and PI3K\/AKT\/mTORC1 Distinct Pathways in Colorectal Cancer? Cell Mol Gastroenterol Hepatol 10(3):491\u2013506","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"12495_CR19","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1038\/s41467-018-05692-6","volume":"9","author":"H Adhikari","year":"2018","unstructured":"Adhikari H, Counter CM (2018) Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat Commun 9(1):3646","journal-title":"Nat Commun"},{"issue":"24","key":"12495_CR20","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.21.02541","volume":"40","author":"KK Ciombor","year":"2022","unstructured":"Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R (2022) BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. J Clin Oncol 40(24):2706\u20132715","journal-title":"J Clin Oncol"},{"issue":"3","key":"12495_CR21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.20517\/cdr.2022.41","volume":"5","author":"AJ Eustace","year":"2022","unstructured":"Eustace AJ, Lee MJ, Colley G, Roban J, Downing T, Buchanan PJ (2022) Aberrant calcium signalling downstream of mutations in TP53 and the PI3K\/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer. Cancer Drug Resist 5(3):560\u2013576","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"12495_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12885-024-12776-8","volume":"24","author":"Y Tang","year":"2024","unstructured":"Tang Y, Fan Y, Combined KRAS (2024) TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis. BMC Cancer 24(1):1155","journal-title":"BMC Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12495-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:02:59Z","timestamp":1786172579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12495-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12495"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12495-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1366"}}